ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL - Episode 3

Obe-Cel and MRD Outcomes: Insights and Comparisons

February 6, 2025

Kristen M. O’Dwyer, MD , Aaron Logan, MD, PhD, John Molina, MD, MEd , Paul J. Shaughnessy, MD

Panelists discuss how real-world outcomes data from the CIBMTR registry on brexucabtagene autoleucel (brexu-cel) presented at the American Society of Hematology Annual Meeting and Exposition (ASH 2024) align with clinical practice, as well as the key findings from the FELIX trial, including minimal residual disease (MRD) outcomes and comparisons with the ZUMA-3 trial for obecabtagene autoleucel (obe-cel) in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

EP. 1: Introduction to CAR T-Cell Therapies in R/R ALL

EP. 2: Clinical Trials and Real-World Data on Brexu-Cel

Now Viewing

EP. 3: Obe-Cel and MRD Outcomes: Insights and Comparisons

EP. 4: Shifting Treatment Paradigms in R/R ALL

Video content above is prompted by the following:

Dr. O’Dwyer to Dr. Logan: There’s been a lot of real-world outcomes data with brexu-cel. Can you share some ASH 2024 data updates from CIBMTR and whether these data reflect what you have observed in your day-to-day clinical practice?
Resource links: ASH 2024 poster 5092, Wudhikarn K et al, brexu-cel CIMBTR registry updates, or see Appendix 2.
Dr. O’Dwyer to Dr. Molina: One of the biggest updates in ALL is the recent FDA approval of obe-cel. Can you review the FELIX trial, including study design and ASH 2024 updates on MRD outcomes? How is this trial similar and different than ZUMA-3?